In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Dyadic International (DYAI – Research Report), with a price target of $6.00. The company’s shares closed yesterday at $2.19.
According to TipRanks, Bernardino is a 5-star analyst with an average return of 14.2% and a 29.80% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Gamida Cell, Cassava Sciences, and GeoVax Labs.
Currently, the analyst consensus on Dyadic International is a Moderate Buy with an average price target of $6.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $3.56 and a one-year low of $1.12. Currently, Dyadic International has an average volume of 39.79K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL.
Read More on DYAI:
- Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
- Dyadic to Participate at Two Industry Events in May
- Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™
- Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
- Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform
